EUVIMEDEUVIMED entdecken
Crossref

Real‐world analysis of metastatic prostate cancer demonstrates increased frequency of PSA‐imaging discordance with visceral metastases and upfront ARAT/docetaxel therapy

Takuto Hara iD, Tomoaki Terakawa iD, Yasuyoshi Okamura, Yukari Bando, Junya Furukawa, Kenichi Harada, Yuzo Nakano, Masato Fujisawa

The Prostate · 2023

DOI: 10.1002/pros.24588 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2023. Verfasst von Takuto Hara und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The objective of this study was to evaluate the background and treatment course of patients with metastatic prostate cancer (PC), with a particular focus on radiographic progression in the absence of prostate‐specific antigen (PSA) progression.

Methods

The study population consisted of 229 patients with metastatic hormone‐sensitive PC (HSPC), who received prostate biopsy and androgen deprivation therapy at Kobe University Hospital between January 2008 and June 2022. Clinical characteristics were retrospectively evaluated using medical records. PSA progression‐free status was defined as ≤1.05 times greater than that from 3 months before. Multivariate analyses were performed using the Cox proportional hazards regression model to identify parameters associated with time to progression on imaging without PSA elevation.

Results

A total of 227 patients with metastatic HSPC without neuroendocrine PC were identified. The median follow‐up period was 38.0 months, with a median overall survival of 94.9 months. Six patients exhibited disease progression on imaging without PSA elevation during HSPC treatment, three during first‐line castration‐resistant PC (CRPC) treatment, and two during late‐line CRPC treatment. The rate of disease progression without PSA elevation at 3 years after treatment initiation was 7.4%. Multivariate analysis revealed that organ metastases and upfront treatment with docetaxel or androgen receptor axis‐targeted therapy were independent prognostic factors for imaging progression without PSA elevation.

Conclusions

Disease progression on imaging without PSA elevation occurred not only during HSPC treatment and first‐line CRPC treatment, but also during late‐line CRPC treatment. Patients with visceral metastases or those treated with upfront androgen receptor axis‐targeted or docetaxel may be more prone to such progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic Neoplasms, Castration-ResistantMaleHumansDocetaxelReceptors, AndrogenAndrogen AntagonistsRetrospective StudiesDisease ProgressionTreatment Outcome

Stichwörter der Autor:innen

CRPCHSPCPSAandrogen deprivation therapy

Substanzen

DocetaxelProstate-Specific AntigenReceptors, AndrogenAndrogen Antagonists

Autor:innen und Institutionen

  • Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.

ORCID-Profile: Takuto Hara, Tomoaki Terakawa

Zitieren

APA

Hara, T., Terakawa, T., Okamura, Y., Bando, Y., Furukawa, J., Harada, K., Nakano, Y., & Fujisawa, M. (2023). Real‐world analysis of metastatic prostate cancer demonstrates increased frequency of PSA‐imaging discordance with visceral metastases and upfront ARAT/docetaxel therapy. The Prostate. https://doi.org/10.1002/pros.24588

Vancouver

Hara T, Terakawa T, Okamura Y, Bando Y, Furukawa J, Harada K, et al. Real‐world analysis of metastatic prostate cancer demonstrates increased frequency of PSA‐imaging discordance with visceral metastases and upfront ARAT/docetaxel therapy. The Prostate. 2023. doi:10.1002/pros.24588

BibTeX
@article{Hara2023,
  author = {Hara, Takuto and Terakawa, Tomoaki and Okamura, Yasuyoshi and Bando, Yukari and Furukawa, Junya and Harada, Kenichi and Nakano, Yuzo and Fujisawa, Masato},
  title = {Real‐world analysis of metastatic prostate cancer demonstrates increased frequency of PSA‐imaging discordance with visceral metastases and upfront ARAT/docetaxel therapy},
  journal = {The Prostate},
  year = {2023},
  doi = {10.1002/pros.24588}
}
Kostenlos starten →